Yang, L.; Ma, A. Cost-Utilities Analysis of Polatuzumab Vedotin Combined With Bendamustine and Rituximab for Relapsed Refractory Diffuse Large B-Cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation. FBEM 2023, 8 (3), 178-184. https://doi.org/10.54097/fbem.v8i3.7835.